EGFR has been the most extensively studied with ... by which this process controls the magnitude and quenching of signaling. Understanding the mechanisms by which receptors interact with one ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation compared with mice with an intact FGFR2 gene. In addition, the combined ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the upcoming presentation of the ...

A new study from Cold Spring Harbor Laboratory, published in Cancer Research, shows that inhibiting the FGFR2 and EGFR proteins in pancreatic cells can delay or even prevent tumor formation.

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...